Grifols SA

GRFS

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    23,822

Stocks News & Analysis

stocks

6 undervalued stocks with low beta

Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,639.301.500.02%
CAC 407,779.728.38-0.11%
DAX 4023,933.23104.96-0.44%
Dow JONES (US)42,215.73117.030.28%
FTSE 1008,716.459.56-0.11%
HKSE23,220.87352.51-1.50%
NASDAQ19,175.8774.930.39%
Nikkei 22537,917.38515.60-1.34%
NZX 50 Index12,378.1796.860.79%
S&P 5005,912.1723.620.40%
S&P/ASX 2008,413.904.100.05%
SSE Composite Index3,344.7218.72-0.56%

Market Movers